Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28592975 | 0.81 | XDH (0.45) | XDHNR3C1PGRNR3C2AR | |
| SCHEMBL31106988 | 0.77 | IMPDH2 (0.61) | XDHMEN1ALDH1A1LMNAGAA | |
| SCHEMBL8266974 | 0.77 | IMPDH2 (0.61) | XDHMEN1ALDH1A1LMNAGAA | |
| SCHEMBL28918792 | 0.76 | MEN1 (0.47) | XDHNR3C1PGRNR3C2AR | |
| SCHEMBL981052 | 0.75 | MAPT (0.43) | NR3C1PGRNR3C2ARKDM4E | |
| SCHEMBL24853984 | 0.72 | SMN1; SMN2 (0.53) | XDHALDH1A1LMNAGAAHTT | |
| SCHEMBL28591150 | 0.72 | XDH (0.51) | XDHKDM4EALDH1A1LMNA | |
| SCHEMBL30173391 | 0.72 | SMN1; SMN2 (0.53) | XDHALDH1A1LMNAGAAHTT | |
| SCHEMBL30173392 | 0.72 | SMN1; SMN2 (0.53) | XDHALDH1A1LMNAGAAHTT | |
| SCHEMBL2706652 | 0.72 | CA12 (0.41) | MEN1ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | XDH 2674/4885NR3C1 2486/4885PGR 4483/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | XDH 160/4885NR3C1 2338/4885PGR 3811/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | XDH 619/4885NR3C1 4099/4885PGR 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.